Catalyst
Slingshot members are tracking this event:
Agenus (AGEN) Shuts Down Phase 2 Study Assessing Prophage G-200 + Roche's (RHHBY) Avastin in Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 22, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2, Termination, Avastin, Prophage G-200, Surgiacally Resectable, Recurrent Glioblastoma Multiforme, Gbm
